Mind Medicine (MindMed) Stock (NASDAQ:MNMD)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$5.46

52W Range

$2.41 - $12.22

50D Avg

$6.61

200D Avg

$6.97

Market Cap

$453.18M

Avg Vol (3M)

$904.64K

Beta

2.36

Div Yield

-

MNMD Company Profile


Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

57

IPO Date

Nov 15, 2016

Website

MNMD Performance


MNMD Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-93.87M$-66.33M$-96.36M
Net Income$-95.73M$-47.26M$-93.04M
EBITDA$-93.87M$-74.37M$-93.75M
Basic EPS-$-1.53$-3.40
Diluted EPS-$-1.53$-3.40

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 24May 08, 24 | 12:00 AM
Q3 23Nov 02, 23 | 12:00 AM
Q2 23Aug 03, 23 | 8:52 PM

Peer Comparison


TickerCompany
CKPTCheckpoint Therapeutics, Inc.
ATAIAtai Life Sciences N.V.
RVPHReviva Pharmaceuticals Holdings, Inc.
EWTXEdgewise Therapeutics, Inc.
GHRSGH Research PLC
BPTHBio-Path Holdings, Inc.
SEELSeelos Therapeutics, Inc.
VCNXVaccinex, Inc.
KODKodiak Sciences Inc.
ITOSiTeos Therapeutics, Inc.
MBIOMustang Bio, Inc.
MOLNMolecular Partners AG
OPTOpthea Limited
ELYMEliem Therapeutics, Inc.